Next 10 |
home / stock / tpst / tpst articles
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining more than 300 points on Thursday. The Dow traded up 0.87% to 3...
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 20...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 50 points on Thursday. Following the market opening Thursd...
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with ...
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard r...
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing ...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-q...
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing...
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing...
News, Short Squeeze, Breakout and More Instantly...
Tempest Therapeutics Inc. Company Name:
TPST Stock Symbol:
NASDAQ Market:
Tempest Therapeutics Inc. Website:
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves ...
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global ran...